Figure 3.
Figure 3. Tolerance to HGG can be induced by administration under the cover of anti-CD4 therapy. (A) CBA mice were pretreated as follows and serum harvested at day 0 for ELISA analysis: tolerizing protocol, 200 μg YTS177 on days -42, -41, and -40 and 500 μg HGG on days -41, -14, and -7; priming protocol, 200 μg YTS177 on days -42, -41, and -40 and 500 μg HGG on days -14 and -7; YTS177/HGG + HGG reactivation protocol for in vivo adoptive transfer, 200 μg YTS177 on days -28 and -27 and 500 μg HGG on days -27 and -1. (B) Anti-HGG antibody titer at day 0. ▵ untreated; • tolerizing protocol; ⋄ priming protocol; ▪ in vivo adoptive transfer protocol; n = 2 in per group. Results are presented as mean ± SD.

Tolerance to HGG can be induced by administration under the cover of anti-CD4 therapy. (A) CBA mice were pretreated as follows and serum harvested at day 0 for ELISA analysis: tolerizing protocol, 200 μg YTS177 on days -42, -41, and -40 and 500 μg HGG on days -41, -14, and -7; priming protocol, 200 μg YTS177 on days -42, -41, and -40 and 500 μg HGG on days -14 and -7; YTS177/HGG + HGG reactivation protocol for in vivo adoptive transfer, 200 μg YTS177 on days -28 and -27 and 500 μg HGG on days -27 and -1. (B) Anti-HGG antibody titer at day 0. ▵ untreated; • tolerizing protocol; ⋄ priming protocol; ▪ in vivo adoptive transfer protocol; n = 2 in per group. Results are presented as mean ± SD.

Close Modal

or Create an Account

Close Modal
Close Modal